Silexion SIL204 shows ~90% inhibition in colorectal cells; expands to lung & pancreatic

Silexion Therapeutics Corp

SIL204 inhibited GP2D colorectal cancer cells with ~90% inhibition rate in preclinical study.
Dose-dependent reduction observed in Panc-1 (pancreatic), A427 (lung) cell lines at nanomolar concentrations.
Company to conduct additional lung (NSCLC) cancer cell line study in coming weeks.
KRAS G12D mutation targeted; addresses pancreatic (~90%), colorectal (~45%), and lung (~35%) cancers.
Ilan Hadar cites SIL204's enhanced lipid-conjugate delivery enabling potent activity at low doses.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.